Loading...
XNYS
GMED
Market cap9.89bUSD
Oct 08, Last price  
73.33USD
1D
-0.57%
1Q
-6.12%
Jan 2017
195.57%
IPO
443.19%
Name

Globus Medical Inc

Chart & performance

D1W1MN
XNYS:GMED chart
P/E
18.39
P/S
3.37
EPS
3.99
Div yield, %
—
Shrs. gr., 5y
6.33%
Rev. gr., 5y
30.08%
Revenues
2.94b
+16.65%
254,344,000288,195,000331,478,000385,994,000434,459,000474,371,000544,753,000563,994,000635,977,000712,969,000785,368,000789,042,000958,102,0001,022,843,0001,568,476,0002,519,355,0002,938,900,000
Net income
538m
+422.31%
48,733,00054,458,00060,784,00073,831,00068,612,00092,485,000112,784,000104,341,000107,348,000156,474,000155,210,000102,285,000149,191,000190,169,000122,873,000102,984,000537,900,000
CFO
753m
+44.72%
32,079,00071,288,00076,410,00076,519,00093,471,00079,172,000121,957,000171,893,000159,535,000181,643,000171,975,000198,793,000276,274,000178,468,000243,499,000520,638,000753,447,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products. These encompass traditional fusion implants like pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices, all designed to treat conditions such as degenerative diseases, deformities, tumors, and trauma. Furthermore, they offer advanced motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also provides interventional pain management options for vertebral compression fractures, alongside a selection of regenerative biologic products such as allografts and synthetic alternatives. Beyond spinal care, Globus Medical manufactures solutions for orthopedic trauma, featuring products like fracture plates, compression screws, intramedullary nails, and external fixation systems. They also specialize in hip and knee joint reconstruction, offering modular hip stems, acetabular cups, and various knee arthroplasty implants, including posterior stabilizing and cruciate retaining designs. Additionally, the company engages in the distribution of human cell, tissue, and other cellular and tissue-based products. Established in 2003, Globus Medical, Inc. maintains its corporate headquarters in Audubon, Pennsylvania.

Related entities

Subsidiaries (2)
GLOBUS MEDICAL INDIA PRIVATE LIMITED
NUVASIVE NETHERLANDS B.V.

Key people

President, Chief Executive Officer, Director · since 2022
Kyle Kline
Chief Financial Officer · since 2025
Chief Financial Officer, Chief Operating Officer · since 2024
David Paul
Executive Chairman of the Board · since 2017
Kelly Huller
Executive Vice President, General Counsel, Corporate Secretary · since 2024
David Davidar
Independent Director · since 2016
Independent Director · since 2023
Robert Douglas
Independent Director · since 2019
Independent Director · since 2011
Independent Director · since 2023
Independent Director · since 2011
Independent Director · since 2015
Independent Director · since 2023
Stephen Zarrilli
Independent Director · since 2019
IPO date
Mar 08, 2012
Employees
2,600
Domiciled in
US
Incorporated in
US
Legal address
251 LITTLE FALLS DRIVE, c/o CORPORATION SERVICE COMPANY
WILMINGTON, DE 19808
US
Headquarters
2560 General Armistead Avenue
Audubon, PA 19403
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT